Advertisement

Tumor Biology

, Volume 36, Issue 3, pp 1685–1693 | Cite as

The polymorphism MMP1 −1607 (1G>2G) is associated with a significantly increased risk of cancers from a meta-analysis

Research Article

Abstract

Growing evidences show that matrix metalloproteinase 1 (MMP1) plays important roles in tumorigenesis and cancer metastasis. MMP1 −1607 1G>2G is a single nucleotide polymorphism in the promoter region of MMP1 and affects MMP1 production. Analysis of previous studies on the association of −1607 1G>2G polymorphism with different cancer types remained to be illustrated. To further assess the effect of −1607 1G>2G polymorphism on cancer risk, we performed this meta-analyses, up to September 8, 2014, of 10,640 cases and 10,915 controls from 42 published case–control designed studies. Statistical analyses were performed using STATA 11.0 software. Crude odds ratios (ORs) with 95 % confidence intervals (CIs) were used to assess the strength of associations. ORs with 95 % CIs for the polymorphism MMP1 −1607 1G>2G and cancer were estimated using fixed and random effects models when appropriate. Significantly increased risks were found in overall under the models of 2G vs.1G, 2G2G vs. 1G1G, 2G2G/1G2G vs. 1G1G, and 2G2G vs. 2G1G/1G1G. Significantly elevated risks were observed in colorectal adenoma under the models of 2G vs. 1G, 2G2G vs. 1G1G, 2G2G/1G2G vs. 1G1G, and 2G2G vs. 2G1G/1G1G and lung cancer and head and neck cancer under the models of 2G vs. 1G. We found that significantly elevated risks were observed in Asian population and hospital-based studies in most comparison models tested. Thus, this meta-analysis indicates that the polymorphism MMP1 −1607 1G>2G is significantly associated with a significantly increased risk of cancers and may provide evidence-based medical certificate to study the cancer susceptibility.

Keywords

MMP1 −1607 (1G>2G) polymorphism Cancer risk 

Notes

Acknowledgments

We thank Dr. Yang Liu for her critical comments of this manuscript.

Conflicts of interest

None

References

  1. 1.
    Yan Y, Liang H, Li T, Li M, Li R, Qin X, et al. The MMP-1, MMP-2, and MMP-9 gene polymorphisms and susceptibility to bladder cancer: a meta-analysis. Tumour Biol. 2014;35(4):3047–52. doi: 10.1007/s13277-013-1395-6.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Shaverdashvili K, Wong P, Ma J, Zhang K, Osman I, Bedogni B. MT1-MMP modulates melanoma cell dissemination and metastasis through activation of MMP2 and RAC1. Pigment Cell Melanoma Res. 2013;27(2):287–96. doi: 10.1111/pcmr.12201.CrossRefGoogle Scholar
  3. 3.
    Sand JM, Larsen L, Hogaboam C, Martinez F, Han M, Rossel LM, et al. MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis—validation of two novel biomarker assays. PLoS ONE. 2013;8:e84934.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hughes BG, Fan X, Cho WJ, Schulz R. MMP-2 is localized to the mitochondria-associated membrane of the heart. Am J Physiol Heart Circ Physiol. 2013;306(5):H764–70. doi: 10.1152/ajpheart.00909.CrossRefPubMedGoogle Scholar
  5. 5.
    Sri MK, Nallari P, Vidyasagar A, Jyothy A, Venkateshwari A. Plasma TGF-beta1, MMP-1 and MMP-3 levels in chronic pancreatitis. Indian J Clin Biochem. 2012;27:152–6.CrossRefGoogle Scholar
  6. 6.
    Kachgal S, Carrion B, Janson IA, Putnam AJ. Bone marrow stromal cells stimulate an angiogenic program that requires endothelial MT1-MMP. J Cell Physiol. 2012;227:3546–55.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lu LS, Chen L, Ding WX, Li K, Wu JJ. Elevated expression of both MDR1 and MMP-2 genes in metastasized lymph node of invasive ductal breast cancer. Eur Rev Med Pharmacol Sci. 2012;16:2037–43.PubMedGoogle Scholar
  8. 8.
    Liu HQ, Song S, Wang JH, Zhang SL. Expression of MMP-3 and TIMP-3 in gastric cancer tissue and its clinical significance. Oncol Lett. 2011;2:1319–22.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Chimal-Ramirez GK, Espinoza-Sanchez NA, Utrera-Barillas D, Benitez-Bribiesca L, Velazquez JR, Arriaga-Pizano LA, et al. MMP1, MMP9, and COX2 expressions in promonocytes are induced by breast cancer cells and correlate with collagen degradation, transformation-like morphological changes in MCF-10A acini, and tumor aggressiveness. Biomed Res Int. 2013;2013:279505.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Du X, Wang S, Lu J, Cao Y, Song N, Yang T, et al. Correlation between MMP1-PAR1 axis and clinical outcome of primary gallbladder carcinoma. Jpn J Clin Oncol. 2011;41:1086–93.CrossRefPubMedGoogle Scholar
  11. 11.
    Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev. 2009;23:1882–94.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Decock J, Hendrickx W, Vanleeuw U, Van Belle V, Van Huffel S, Christiaens MR, et al. Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. BMC Cancer. 2008;8:77.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Zhang C, Song X, Zhu M, Shi S, Li M, Jin L, et al. Association between MMP1–1607 1G>2G polymorphism and head and neck cancer risk: a meta-analysis. PLoS ONE. 2013;8:e56294.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Fakhoury H, Noureddine S, Chmaisse HN, Tamim H, Makki RF. MMP1-1607(1G>2G) polymorphism and the risk of lung cancer in Lebanon. Ann Thorac Med. 2012;7:130–2.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Xiao XY, Wang XD, Zang DY. MMP1-1607 1G/2G polymorphism and lung cancer risk: a meta-analysis. Tumour Biol. 2012;33:2385–92.CrossRefPubMedGoogle Scholar
  16. 16.
    Majsterek I, Markiewicz L, Przybylowska K, Gacek M, Kurowska AK, Kaminska A, et al. Association of MMP1-1607 1G/2G and TIMP1 372 T/C gene polymorphisms with risk of primary open angle glaucoma in a Polish population. Med Sci Monit. 2011;17:R417–21.CrossRefGoogle Scholar
  17. 17.
    Hashimoto T, Uchida K, Okayama N, Imate Y, Suehiro Y, Hamanaka Y, et al. Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. Cancer Lett. 2004;211:19–24.CrossRefPubMedGoogle Scholar
  18. 18.
    Zinzindohoue F, Blons H, Hans S, Loriot MA, Houllier AM, Brasnu D, et al. Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma. Anticancer Res. 2004;24:2021–6.PubMedGoogle Scholar
  19. 19.
    Kondo S, Wakisaka N, Schell MJ, Horikawa T, Sheen TS, Sato H, et al. Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. Int J Cancer. 2005;115:368–76.CrossRefPubMedGoogle Scholar
  20. 20.
    O-charoenrat P, Leksrisakul P, Sangruchi S. A functional polymorphism in the matrix metalloproteinase-1 gene promoter is associated with susceptibility and aggressiveness of head and neck cancer. Int J Cancer. 2006;118:2548–53.CrossRefPubMedGoogle Scholar
  21. 21.
    Lin SC, Chung MY, Huang JW, Shieh TM, Liu CJ, Chang KW. Correlation between functional genotypes in the matrix metalloproteinases-1 promoter and risk of oral squamous cell carcinomas. J Oral Pathol Med. 2004;33:323–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Cao ZG, Li CZ. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances oral squamous cell carcinoma susceptibility in a Chinese population. Oral Oncol. 2006;42:32–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Vairaktaris E, Yapijakis C, Derka S, Serefoglou Z, Vassiliou S, Nkenke E, et al. Association of matrix metalloproteinase-1 (−1607 1G/2G) polymorphism with increased risk for oral squamous cell carcinoma. Anticancer Res. 2007;27:459–64.PubMedGoogle Scholar
  24. 24.
    Shimizu Y, Kondo S, Shirai A, Furukawa M, Yoshizaki T. A single nucleotide polymorphism in the matrix metalloproteinase-1 and interleukin-8 gene promoter predicts poor prognosis in tongue cancer. Auris Nasus Larynx. 2008;35:381–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Gao W, Sui J, Wang BQ, Ling XJ, Zhang CM, Wen SX, et al. MMP-1 (−1607) 1G/2G gene polymorphism and susceptibility to nasopharyngeal in Han population in Yunnan China. China otolaryngol head and neck surg. 2010;03:116–20.Google Scholar
  26. 26.
    Chaudhary AK, Singh M, Bharti AC, Asotra K, Sundaram S, Mehrotra R. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J Biomed Sci. 2010;17:10.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    McCready J, Broaddus WC, Sykes V, Fillmore HL. Association of a single nucleotide polymorphism in the matrix metalloproteinase-1 promoter with glioblastoma. Int J Cancer. 2005;117:781–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Bradbury PA, Zhai R, Hopkins J, Kulke MH, Heist RS, Singh S, et al. Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis. 2009;30:793–8.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Cheung WY, Zhai R, Bradbury P, Hopkins J, Kulke MH, Heist RS, et al. Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma. Int J Cancer. 2012;131:2478–86.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Su L, Zhou W, Asomaning K, Lin X, Wain JC, Lynch TJ, et al. Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis. 2006;27:1024–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Zhang WQ, Lin H, Zhou YA, Wang YJ, Cheng QS. Association of MMP1-1607 (1G→2G) single nucleotide polymorphism with susceptibility to lung cancer in Northwestern Chinese population of Han nationality. Chin J Med Genet. 2006; :313–315.Google Scholar
  32. 32.
    Cheng XL. Correlation o f single nucleotide polymorphism in them atrixmetalloproteinase-1 gene promoter (−1607) 1G / 2G with risk o f lung cancer. J Shanxi Med Univ. 2007:777–779.Google Scholar
  33. 33.
    Wei WQ, Liang XQ, Wen XP. The Association of MMP-1-1607 (1G→2G) single nucleotide polymorphism with the susceptibility to non-small cell lung carcinoma in Guizhou Han nationality. J Guiyang Med Coll. 2007:267–269.Google Scholar
  34. 34.
    Hart K, Landvik NE, Lind H, Skaug V, Haugen A, Zienolddiny S. A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. Lung Cancer. 2011;71:123–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Liu L, Wu J, Wu C, Wang Y, Zhong R, Zhang X, et al. A functional polymorphism (−1607 1G–>2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer. Cancer. 2011;117:5172–81.CrossRefPubMedGoogle Scholar
  36. 36.
    Gonzalez-Arriaga P, Lopez-Cima MF, Fernandez-Somoano A, Pascual T, Marron MG, Puente XS, et al. Polymorphism +17 C/G in matrix metalloprotease MMP8 decreases lung cancer risk. BMC Cancer. 2008;8:378.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Hinoda Y, Okayama N, Takano N, Fujimura K, Suehiro Y, Hamanaka Y, et al. Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer. 2002;102:526–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Elander N, Soderkvist P, Fransen K. Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer Res. 2006;26:791–5.PubMedGoogle Scholar
  39. 39.
    Woo M, Park K, Nam J, Kim JC. Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol. 2007;22:1064–70.CrossRefPubMedGoogle Scholar
  40. 40.
    Kouhkan F, Motovali-Bashi M, Hojati Z. The influence of interstitial collagenase-1 genotype polymorphism on colorectal cancer risk in Iranian population. Cancer Invest. 2008;26:836–42.CrossRefPubMedGoogle Scholar
  41. 41.
    Srivastava P, Gangwar R, Kapoor R, Mittal RD. Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. Dis Markers. 2010;29:37–46.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Tasci AI, Tugcu V, Ozbek E, Ozbay B, Simsek A, Koksal V. A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility. BJU Int. 2008;101:503–7.PubMedGoogle Scholar
  43. 43.
    Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, et al. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res. 2006;66:11644–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Ye S, Dhillon S, Turner SJ, Bateman AC, Theaker JM, Pickering RM, et al. Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. Cancer Res. 2001;61:1296–8.PubMedGoogle Scholar
  45. 45.
    Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, et al. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res. 2002;8:3820–3.PubMedGoogle Scholar
  46. 46.
    Hirata H, Naito K, Yoshihiro S, Matsuyama H, Suehiro Y, Hinoda Y. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma. Int J Cancer. 2003;106:372–4.CrossRefPubMedGoogle Scholar
  47. 47.
    Ju W, Kang S, Kim JW, Park NH, Song YS, Kang SB, et al. Promoter polymorphism in the matrix metalloproteinase-1 and risk of cervical cancer in Korean women. Cancer Lett. 2005;217:191–6.CrossRefPubMedGoogle Scholar
  48. 48.
    Lai HC, Chu CM, Lin YW, Chang CC, Nieh S, Yu MH, et al. Matrix metalloproteinase 1 gene polymorphism as a prognostic predictor of invasive cervical cancer. Gynecol Oncol. 2005;96:314–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Matsumura S, Oue N, Nakayama H, Kitadai Y, Yoshida K, Yamaguchi Y, et al. A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol. 2005;131:19–25.CrossRefPubMedGoogle Scholar
  50. 50.
    Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, et al. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat. 2006;95:65–72.CrossRefPubMedGoogle Scholar
  51. 51.
    Affara M, Dunmore BJ, Sanders DA, Johnson N, Print CG, Charnock-Jones DS. MMP1 bimodal expression and differential response to inflammatory mediators is linked to promoter polymorphisms. BMC Genomics. 2011;12:43.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Li M, Moeen RA, Chavez-Munoz C, Lai A, Ghahary A. Keratinocyte-releasable factors increased the expression of MMP1 and MMP3 in co-cultured fibroblasts under both 2D and 3D culture conditions. Mol Cell Biochem. 2009;332:1–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Hu J, Pan J, Luo ZG. MMP1 rs1799750 single nucleotide polymorphism and lung cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:5981–4.CrossRefPubMedGoogle Scholar
  54. 54.
    Ricketts C, Zeegers MP, Lubinski J, Maher ER. Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma. PLoS ONE. 2009;4(6):e6037.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Morosova EB, Chukhlovin AB, Kulagina NV, Kipich NV, Totolian AA. Functional gene polymorphism of matrix metalloproteinase-1 is associated with benign hyperplasia of myo- and endometrium in the Russian population. Genet Test Mol Biomarkers. 2012;16(9):1032–7.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Nishizawa R, Nagata M, Noman AA, Kitamura N, Fujita H, Hoshina H, et al. The 2G allele of promoter region of matrix metalloproteinase-1 as an essential pre-condition for the early onset of oral squamous cell carcinoma. BMC Cancer. 2007;7:187.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Dey S, Ghosh N, Saha D, Kesh K, Gupta A, Swarnakar S. Matrix metalloproteinase-1 (MMP-1) promoter polymorphisms are well linked with lower stomach tumor formation in eastern Indian population. PLoS ONE. 2014;9(2):e88040.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Zhai Y, Qiu W, Dong XJ, Zhang XM, Xie WM, Zhang HX, et al. Functional polymorphisms in the promoters of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12 and MMP-13 are not associated with hepatocellular carcinoma risk. Gut. 2007;56(3):445–7.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Biology, College of Life and Environmental SciencesShanghai Normal UniversityShanghaiChina
  2. 2.Department of Traditional Chinese Medicine, Renji Hospital, School of MedicineShanghai Jiao Tong UniversityShanghaiChina

Personalised recommendations